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Lytic replicationLytic cycle reactivation of Kaposi's sarcoma-associated herpesvirus (KSHV) is initiated by expression of the
ORF50 gene. Here we show that YY1 protein speciﬁcally binds to the ORF50 promoter (ORF50p) region in vitro
and in vivo. After treatment with chemical inducers, including sodium butyrate (SB) and TPA, the levels of YY1
protein are inversely correlated with the lytic induction of KSHV in cells. Overexpression of YY1 completely
blocks the ORF50p activation in transient reporter assays, while mutation at the YY1 site in the ORF50p or
knockdown of YY1 protein confers an enhancement of the ORF50p activation induced by SB and TPA. YY1
overexpression in a stable cell clone HH-B2(Dox-YY1) also inhibits expression of the ORF50 and its
downstream lytic genes. On the other hand, a chimeric YY1 construct that links to its coactivator E1A can
disrupt viral latency. These results imply that YY1 is involved in the regulation of KSHV reactivation.ng).
l rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
Kaposi's sarcoma-associated herpesvirus (KSHV) or human
herpesvirus-8 (HHV-8) is a gamma herpesvirus associated with at
least three human malignancies, including Kaposi's sarcoma, primary
effusion lymphoma (PEL), and multicentric Castleman's disease
(Cesarman et al., 1995; Chang et al., 1994; Soulier et al., 1995). Like
all herpesviruses, KSHV manifests two distinct phases of its life cycle,
latency and lytic replication (Miller et al., 1997; Miller et al., 1996).
Various environmental or chemical inducers that trigger the switch
between KSHV latency and lytic replication have been identiﬁed,
including hypoxia, endoplasmic reticulum (ER) stress, 12-O-tetra-
decanoylphorbol-13-acetate (TPA), sodium butyrate, epinephrine,
norepinephrine and proinﬂammatory cytokines as well as super-
infection with other viruses (Chang et al., 2000; Dalton-Grifﬁn et al.,
2009; Davis et al., 2001; Lu et al., 2005; Miller et al., 1997; Wilson
et al., 2007). However, the authentic physiological stimuli for KSHV
reactivation are still not well understood.
During KSHV reactivation from latency, a transcriptional activator
encoded in open reading frame 50 (ORF50) of the viral genome is
expressed at the earliest stage and functions as a molecular switch to
initiate the viral lytic cascade to completion (Gradoville et al., 2000;
Sun et al., 1998). Since the ORF50 protein is a key controller of KSHVreactivation, much attention has been focused on the characteriza-
tion of the ORF50 promoter. Several important cis-elements in the
ORF50 promoter speciﬁcally conferring the response to various
stimuli have been partly identiﬁed, such as three related HIF-1α-
binding sites for hypoxia induction; an XBP-1 site for ER stress; an
SP1 site for n-butyrate induction; an AP-1 site for TPA induction (Cai
et al., 2006; Dalton-Grifﬁn et al., 2009; Lu et al., 2003; Wang et al.,
2004a; Ye et al., 2005). Most of these identiﬁed regulatory elements
do not overlap each other, suggesting that KSHV in cells must have
evolved numerous independent pathways to regulate the ORF50
promoter in response to different stimuli. In addition to the exogenous
stimuli, ORF50 protein also auto-stimulates its own promoter
mediating through RBP-Jκ, Oct1 or C/EBPα sites under certain
conditions (Liang and Ganem, 2003; Sakakibara et al., 2001; Wang
et al., 2003). Due to the poor understanding of the physiological and
environmental stimuli on KSHV reactivation, only a few transcrip-
tional factors are known to regulate the ORF50 promoter.
YY1 is a multifunctional transcriptional factor implicated in both
positive and negative regulation of a diverse number of cellular and
viral promoters (Hyde-DeRuyscher et al., 1995; Shi et al., 1997). It is a
sequence-speciﬁc DNA binding protein that recognizes a conserved
5′-(C/g/a)(G/t)(C/t/a)CATN(T/a)(T/g/c), where the upper case letters
represent the preferred bases (Hyde-DeRuyscher et al., 1995). In
addition to tethering on DNA promoter, YY1 also interacts with a wide
variety of transcription factors or modulators, including TATA binding
protein, TFIIB, SP1, c-Myc, ATF/CREB, C/EBP, TAFII55, p300, CREB-
binding protein (CBP), HDAC1, HDAC2, HDAC3 and adenovirus E1A
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particular interest, which converts YY1 froma repressor to an activator
(Lee et al., 1995a, 1995b). In general, YY1 as a transcriptional repressor
or activator depends on its relative concentration, its associated
proteins and the promoter context surrounding the YY1 binding sites.
In this study, we identify that YY1 protein speciﬁcally binds to the
ORF50 promoter in vitro and in the latently KSHV-infected cells. The
potential roles of YY1 in regulating the viral reactivation under
different conditions were discussed.
Materials and methods
Cell cultures and transfections
HKB5/B5 is a cell clone derived from the fusion of HH514–16 cells
with 293 T cells (Chang et al., 2002). The HKB5/B5 cells were cultured
in RPMI 1640 medium supplemented with 8% fetal bovine serum
(FBS). HH-B2, a primary effusion lymphoma cell line infected with
KSHV (Gradoville et al., 2000), was grown in RPMI 1640 medium
supplemented with 15% FBS. HH-B2(Dox-YY1) cell clones harboring a
doxycycline (Dox)-regulated YY1 gene were established from HH-B2
cells by two selection steps according to user manual of the Tet-On
Advanced Inducible Gene Expression System (Clontech). One of the
selected clones was used in the study and was maintained in the
medium with 100 μg G418 per ml and 400 μg hygromycin per ml. For
induction of the exogenous YY1, doxycycline (Sigma) was added in
1 μg per ml. In addition, treatment of cells with sodium butyrate
(3 mM), TPA (30 ng/ml) or cycloheximide (100 μg/ml) was per-
formed in some experiments. Cell proliferation was measured by
trypan blue staining. All transfection assays were carried out using
Lipofatamine 2000 (Invitrogen).
Plasmid construction
The reporter plasmids containing the ORF50p region from−3801
to +10, −1365 to +10, and −220 to +10 were constructed by
inserting the corresponding regions into pGL3-basic (Promega) with
XhoI and HindIII sites. Mutation of the YY1 site in the ORF50 promoter
was generated using the QuickChang site-directed mutagenesis kit
(Stratagene). Plasmids pCMV, pCMV–FLAG–ORF50(1–490) and
pCMV–FLAG–ORF50 have been previously described (Chang and
Miller, 2004). An E1A expression vector, pCMV–FLAG–E1A, was
generated by use of reverse transcription-PCR to amplify the full-
length 13S E1A cDNA from 293 cells using 5′-GGGGAATTCAATGAGA-
CATATTATCTGCCA-3 and 5′-TTTAGATCTTATGGCCTGGGGCGTTTA-
CAG-3′. The E1A cDNA fragment was cloned into pFLAG–CMV-2
(Sigma) with EcoRI and BglII sites. The plasmids pCMV–FLAG–YY1
and pCMV–FLAG–YY1–E1A were generated by inserting the YY1Fig. 1. Schematic diagram of the ORF50 promoter region and the location of an YY1 bindi
positions relative to the transcription start site and positions of the KSHV genome. The kn
included in the diagram. Sequence alignment between the YY1-binding site in the ORF50 pro
the consensus YY1 recognition sequence indicate the preferred base for YY1 binding, whilecoding region into pFLAG–CMV-2 with EcoRI and BglII sites and into
pCMV–FLAG–E1A with EcoRI site. These YY1 DNA fragments were
ampliﬁed using pCMV–YY1 (kindly provided by Thomas Shenk at
PrincetonUniversity) as a template by PCR. The plasmids pPAN/E4-luc,
pK12/E4luc, pK6/E4luc and pORF57/E4luc were constructed by
inserting double-stranded annealed oligonucleotides encompassing
the ORF50 response elements from the PAN, K12, vMIP-1 and ORF57
promoters (Chang et al., 2005) into the XhoI and NheI sites of pE4-Luc,
a luciferase reporter containing an adenovirus E4 minimal promoter
(Chang et al., 2008).
Electrophoretic mobility shift assay (EMSA)
The probe was end-labeled with [γ-32P]ATP by T4 polynucleotide
kinase or was end-labeled with biotin-11-UTP by terminal deoxynu-
cleotidyl transferase (Chang et al., 2010). Extracts of HKB5/B5 cells
transfected with the expression plasmids were prepared as described
previously (Chang and Miller, 2004). The reaction mixture of EMSA
contained 15 μg protein extract and 2 ng probe in a solution containing
10 mM HEPES (pH 7.5), 50 mM NaCl, 2 mM MgCl2, 2.5 μM ZnSO4,
0.5 mMEDTA, 1 mMdithiothreitol, 15% glycerol, and 0.3–0.5 μg of poly
(dI–dC) in a total volume of 20 μl.
Chromatin immunoprecipitation (ChIP) assay
HH-B2 cells (2×106) were incubated with 1% formaldehyde for
10 min at 37 °C. Cell lysates were prepared and immunoprecipitated
as described previously (Wang et al., 2010). Monoclonal antibody to
YY1 (sc-7341; Santa Cruz) and polyclonal antibodies to YY1 (sc-1703;
Santa Cruz) and actin (sc-1616; Santa Cruz) were used in ChIP assay.
The primers for ampliﬁcation of the ORF50 promoter region were 5′-
CGCTAAGAACCCCGGGTGTC-3′ and 5′-CTACCCCTTGCGGAGTAAGG-3′.
The primers for ampliﬁcation of the ORF65 coding region were 5′-
AAAAGTGGCCGCCCTATCGGCGT-3′ and 5′-TGGAAGATGTCCAACTT-
TAAGGT-3′.
Western blot analysis
Cell protein extracts were mixed with 3× sodium dodecyl sulfate
(SDS) gel loading buffer and boiled for 5 min before proteins were
resolved on 8% to 10% polyacrylamide gel and transferred to PVDF
membrane (Bio-Rad). The membranes were probed with speciﬁc
antibodies as described previously (Wang et al., 2010). The rabbit
polyclonal antibody against ORF50 protein was generated using
bacterially produced ORF50 protein (aa 1 to 590) as an antigen.
Antibodies to K8 (sc-57889; Santa Cruz), YY1 (sc-1703, sc-7341;
Santa Cruz), GAPDH (sc-20357; Santa Cruz), actin (MAB101;
Chemicon) and FLAG (M2, Sigma) were obtained commercially.ng sequence. Numbers present in the ORF50 promoter region indicate the nucleotide
own binding sites for cellular transcription factors within the ORF50 promoter were
moter and the consensus YY1 recognition sequence was shown. The uppercase letters of
the lowercase letters represent possible substitutions.
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RT-PCR (RT-qPCR)
Total RNAs were isolated from HH-B2 or HH-B2(Dox-YY1) cells
by using an RNeasy kit (QIAGEN) in combination with RNase-free
DNase set (QIAGEN). The amount of the total RNA as a template for
RT-qPCR ranged from 10 to 100 ng. The SuperScript III Platinum
SYBR Green One-Step qRT-PCR kit (Invitrogen) was used to amplify
the target gene fragments. The individual PCR primer sequences
used in RT-qPCR were following: 5′-AGATGACAAGGGTAAGAAGC-3′
and 5′-CGCACCAAGCTTGGAACATTC-3′ for ORF50, 199-bp PCRFig. 2. Binding of YY1 to the ORF50 promoter in vitro and in vivo. (A) YY1 protein speciﬁcally b
−168) was used as a probe in EMSA. The probe was end-labeled either with [γ-32P]ATP by T4
transferase (right panel). Extracts from HKB5/B5 cells transfected with either pCMV or pCMV
and 100-foldmolar excesses over the probe for competition assay in the left panel andwere in
to supershift the YY1/DNA complex. (B) Chromatin immunoprecipitation exploring the asso
performed with mouse monoclonal antibody to YY1 (YY1 mAb), rabbit polyclonal antibody
antibody (no Ab). Input DNA represents 5% of the sample. Ampliﬁcation of the ORF50 promotproduct; 5′-GAAGAGGAACGCTTATGCACTAAGG-3′ and 5′-
AGCTGTCTTGTGTATGCTTTCGATG-3′ for K8, 155 bp; 5′-GGACATTAT-
GAAGGGCATCCTAGAG-3′ and 5′-GACTGGGTACCACGGATGCGCTCGT-
3′ for ORF57, 153 bps; 5′-TGCATTGGATTCAATCTCCAGGCCA-3′ and
5′-GTAGTGCACCACTGTTCTGATACAC-3′ for PAN, 134 bps; 5′-GAAT-
ACCTGGCATTGACCTC-3′ and 5′-TCATGGCCGAGTTATCCCTG-3′ for
YY1, 150 bps; 5′-GGACTTCGAGCAAGAGATGG-3′ and 5′-AGCACTG-
TGTTGGCGTACAG-3′ for actin, 234 bps; 5′-TCATGGGTGTGAACCAT-
GAG-3′ and 5′-AGTGATGGCATGGACTGTGG-3′ for glyceraldehydes-3-
phosphate dehydrogenase (GAPDH), 152 bp. To selectively amplify
the endogenous ORF50 mRNA, but not the exogenous ORF50 mRNAound to ORF50p(−199 to−168). A double-stranded oligonucleotide ORF50p(−199 to
polynucleotide kinase (left panel) or with biotin-11-UTP by terminal deoxynucleotidyl
–FLAG–ORF50(1–490) were prepared and used in EMSAs. Cold competitors were in 50-
20-, 50- and 100-fold in the right panel. Monoclonal antibody speciﬁc for YY1was used
ciation between YY1 and the ORF50 promoter in HH-B2 cells. Immunoprecipitation was
to YY1 (YY1 pAb), goat polyclonal antibody to actin (actin pAb), or without addition of
er or the ORF65 coding region from the immunoprecipitates was examined in the study.
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different set of the ORF50 primers was used. The speciﬁc primers
for amplifying the endogenous ORF50 gene were 5′-GAGAATA-
CTGTCCAGGCAGCCACA and 5′-TGCATGCGGCTGTCAGAAATGCCT-3,
which showed the production of a 421-bp fragment.
DNA afﬁnity precipitation assay (DAPA)
Synthetic ORF50p (−199 to −168) duplex with 5′-conjugated
biotin was used in the DAPA assay. Protein extracts of 5×106 HKB5/B5
cells transfected with pCMV, pCMV–FLAG–YY1, pCMV-FLAG–YY1–
E1A and pCMV–FLAG–E1A were prepared in 400 μl of lysis bufferFig. 3. Down-regulation of YY1 during KSHV lytic induction in HH-B2 cells. (A) HH-B2 cell tr
harvested and examined for the expression of the indicated proteins. (B) Western blot analy
TPA. The mRNA levels of the indicated genes relative to GAPDH by reverse-transcription-qPC
cycloheximide (CHX) for the time periods indicated. Densities of YY1 bands were quantiﬁe(50 mM Tris-Cl [pH 7.5], 150 mM NaCl, 1% NP-40, 1 mM EDTA, 5%
glycerol). The protein lysates were ﬁrst incubated with 200 ng of the
biotinylated duplex for 1 hr at 25 °C and then 70 μl of the streptavidin-
conjugatedmagnetic beads (Promega) were added in themixture and
incubated for an additional hr. After extensive washing, the precipi-
tated protein complexes were subjected to Western blot analysis.
Luciferase assays
HKB5/B5 cells or HH-B2 cells (7×105) in 24-well plates were
transfected with a ﬁxed amount (1 μg) of the reporter and effector
plasmids. Cells were harvested at indicated time points aftereated with sodium butyrate (SB), TPA or both (SB/TPA) for different time periods were
ses and reverse transcription-qPCR were performed in HH-B2 cells treated with SB and
R were shown. (C) HH-B2 cells in the presence or absence of SB/TPA were treated with
d by normalization to actin using the 0 hour group as a normal control.
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times, and individual samples in each experiment were in duplicate.
Preparation of cell lysates and measurement of luciferase activity
were performed according to the manufacturer's protocol for the
luciferase reporter assay system (Promega). Fold-activation was
calculated as luciferase activity in the presence of inducers or effectors
divided by luciferase activity in the presence of control treatments.
RNA interference
For YY1 knockdown, 20 nM of the speciﬁc siRNAs to YY1 (Stealth
YY1 siRNAs; Invitrogen) or a control duplex (Stealth RNAi Negative
Control LO GC, 12935–200; Invitrogen) were used in the study. SenseFig. 4. Repression of the chemical-mediated ORF50p activation by YY1 in transient tran
determined in HKB5/B5 cells and in HH-B2 cells in the presence or absence of SB/TPA. The
constructed into pGL3-Basic. Fold activation of the reporters by SB/TPA was calculated as th
activity of the reporter in the untreated cells. (B) Effect of YY1 overexpression 25 on the ac
pCMV or pCMV-FLAG-YY1 with the ORF50 reporter into HH-B2 cells, the transfected cells w
by SB/TPA was calculated as described above. (C) HH-B2 cells were co-transfected with the
cells were treated with SB/TPA for 18 hr and 24 hr. The luciferase activity was measured as
HKB5/B5 and in HH-B2 cells was measured by Western blot analysis.strands of the YY1 siRNAs were: siYY1-1, 5′-CAUCUUAACACAUGCU-
AAGGCCAAA-3′; siYY1-2, 5′-CAAGAACAAUAGCUUGCCCUCAUAA-3′;
siYY1-3, 5′-CCGAGAUCGUGGAGCUGCACGAGAU-3′.
Northern analysis
RNA samples (25 μg per lane) were fractionated on 1% formalde-
hyde-agarose gels, and transferred to nylon membrane (Hybond-N;
Amersham Pharmacia Biotec). The PAN probe corresponding to the
region between nt 28972 and 29546 of KSHV genome (Russo et al.,
1996) was labeled with 0.1 M digoxigenin (DIG) DNA labeling mix
(Roche) by PCR. Hybridization was performed according to the
protocol described previously (Wang et al., 2010).sfection assay. (A) The wild-type and YY1-mutated ORF50 promoter activities were
ORF50 promoter regions (from −3801 to +10) with or without YY1 mutation were
e luciferase activity of the reporter in the SB/TPA-treated cells divided by the luciferase
tivation of the ORF50p reporter induced by SB/TPA. At 6-hr post-transfection of either
ere then treated with SB/TPA for 18 hr and 24 hr. Fold activation of the ORF50 promoter
ORF50p reporter and the indicated siRNAs. After 6-hr posttransfection, the transfected
described above. The efﬁcacy of the double-stranded siRNAs in knocking down YY1 in
199P.-J. Chang et al. / Virology 413 (2011) 194–204Results
YY1 protein binds to the ORF50 promoter in vitro and in vivo
Sequence analysis of the ORF50 promoter revealed that there was
a perfect matched binding element for cellular transcription factor
YY1 in the ORF50 promoter (Fig. 1). The putative YY1 element, 5′-
CTCCATGTT-3′, is located between nucleotide (nt)−184 and−176 of
the ORF50 promoter, which does not overlap with the previously
identiﬁed regulatory elements (Chang et al., 2005; Russo et al., 1996).
To determine the binding of YY1 to the ORF50 promoter, a segment of
the ORF50 promoter, ORF50p(−199 to−168), was used as a probe in
electrophoretic mobility shift assays (EMSAs). As shown in Fig. 2A, the
ORF50(1–490) protein, which contains the N-terminal 490-aa DNA
binding domain (Chang and Miller, 2004), did not bind to the probe
(Fig. 2A, compare lanes 2–7 with lanes 8–13 in the left panel). Several
cellular proteins that bound to ORF50p(−199 to −168) were
detected in EMSA. When a conserved YY1-binding sequence (rpL30)
from mouse ribosomal protein L30 gene (Perry, 2005) was used as a
cold competitor, a dominant complex formed in EMSA was com-
pletely abolished (Fig. 2A, left panel, lanes 3, 4, 9 and 10). However, a
cold competitor with a mutated YY1 sequence (rpL30-mt) had no
effect on the complex formation (Fig. 2A, left panel, lanes 5, 6, 11 and
12), indicating that YY1 was the main protein binding to ORF50pFig. 5. Overexpression of YY1 blocked the KSHV lytic cycle induced by SB/TPA in HH-B2(Dox
cells that harbor a doxycycline-regulated YY1 were pretreated with doxycycline (1 μg/ml) fo
(B) Cell proliferation of HH-B2(Dox-YY1) in the presence or absence of doxycycline. (C) In
pretreated with doxycycline or in amock treatment for 6 hr. After the 6-hr pretreatment, the
actin in the cells was determined byWestern blot analysis. (D) Induction of lytic cycle genes
were performed as in (C).(−199 to−168). Furthermore, antibody speciﬁc to YY1 signiﬁcantly
removed the same complex in EMSA (Fig. 2A, left panel, lanes 7 and
13). To further locate the YY1 site within the ORF50p(−199 to−168)
element, the central 5′-TCCATG-3′ sequence in the putative YY1-
binding site was mutated to 5′-GAATTC-3′. In a competition analysis,
only the wild-type element, but not the mutant element, competed
for YY1 protein binding to the probe (Fig. 2A, right panel). These
results demonstrated that the region from −184 to −176 of the
ORF50 promoter is a core element for YY1 binding.
To examine whether YY1 protein bound the ORF50 promoter in
latently KSHV-infected cells, chromatin immunoprecipitation assay
(ChIP) was carried out in HH-B2 cells. As shown in Fig. 2B, antibodies
to YY1 were able to immunoprecipitate the speciﬁc ORF50 promoter
region (Fig. 2B, lanes 4 and 5). However, there was no detectable
ORF50 promoter region precipitated by using anti-actin antibody or in
the absence of antibody under the same condition. Therefore, YY1
protein also binds the ORF50 promoter in vivo.
Association between YY1 down-regulation and KSHV lytic induction in
HH-B2 cells after chemical treatment
Binding of YY1 to the ORF50 promoter prompted us to examine the
YY1 expression during the latent-lytic switch of KSHV. To determine
the expression kinetics of YY1 during KSHV lytic cycle, HH-B2 cells-YY1). (A) Induction of YY1 expression in HH-B2(Dox-YY1) cells. The HH-B2(Dox-YY1)
r the indicated time points. Expression of YY1 was determined byWestern blot analysis.
duction of lytic cycle genes in HH-B2(Dox-YY1) cells. The HH-B2(Dox-YY1) cells were
cells were then treated or untreated with SB/TPA. The expression of ORF50, K8, YY1 and
in the parental HH-B2 cells pretreated with doxycycline. The same chemical treatments
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12 h, 24 h and 48 h. Protein extracts of the treated HH-B2 cells were
subjected to Western blot analyses. Cells treated with SB or SB/TPA
signiﬁcantly resulted in reduction of YY1 protein levels in HH-B2 cells.
However, TPA alone did not affect the YY1 level during the same
period. Importantly, we found that activation of the KSHV lytic cycle
proteins, ORF50 and K8, was strongly associated with the down-
regulation of YY1 (Fig. 3A). To further characterize the YY1 down-
regulation after SB/TPA treatment, total RNAs of HH-B2 cells treated
with SB/TPA were prepared and subjected to reverse transcription-
qPCR. As expected, the viral lytic genes, such as ORF50, K8, PAN and
ORF57, could be robustly induced in HH-B2 cells after treatment with
SB/TPA (Fig. 3B). Although the protein levels of YY1 were
dramatically reduced in HH-B2 cells after SB/TPA treatment, the
levels of the YY1 mRNAs in the same cells remained constant
(Fig. 3B). To determine the turnover rate of the YY1 protein in the
untreated and SB/TPA-treated cells, the cells were exposed to
cycloheximide, an inhibitor of protein biosynthesis, to inhibit the
production of the newly synthesized proteins. As shown in Fig. 3C,
YY1 protein had a shorter half-life in cells treated with SB/TPA than
in untreated cells.Fig. 6. Binding of the chimeric YY1–E1A to the YY1 site of the ORF50 promoter. (A) Diagram
to −168). Protein extracts were prepared from HKB5/B5 cells transfected with pCMV, pCM
with 3′-biotin-labeled ORF50p(−199 to −168). Antibody against FLAG was used to supers
DNA afﬁnity precipitation assay (DAPA). The ORF50p(−199 to −168) probe was biotinyl
transfected cells and then were precipitated with streptavidin-conjugated magnetic beads
FLAG and YY1.YY1 inhibits the activation of the ORF50 promoter after SB/TPA treatment
To determine whether YY1 directly affected the activation of the
ORF50 promoter, a 3.8-kb ORF50 promoter with or without the
mutation of the YY1 site was constructed into a luciferase reporter,
pGL3-basic (Fig. 4A). In transient reporter assays, both wild type and
YY1-mutated ORF50 promoter exhibited equal promoter activities in
HKB5/B5 and in HH-B2 cells (Fig. 4A). However, under the lytic
condition induced by SB/TPA, the YY1-mutated ORF50 promoter
exhibited a better response to SB/TPA than the wild-type promoter
(Fig. 4A). When the ORF50p reporter was cotransfected with the YY1-
expressing plasmid into HH-B2 cells, activation of the ORF50
promoter by SB/TPA was completely blocked (Fig. 4B). Although the
YY1 expression was known to be down-regulated during lytic
induction, further knockdown of YY1 in HH-B2 cells by siRNAs was
also used to determine the effect of YY1 on the activation of the ORF50
promoter. After 6-hr pretreatment with the YY1-speciﬁc siRNAs, the
activation of the ORF50p reporter was signiﬁcantly enhanced at
earlier time point (18 hr) after SB/TPA treatment (Fig. 4C). However,
there were no signiﬁcant differences in the ORF50p activation after
24 hr SB/TPA treatment between YY1 siRNA transfected cells andof the YY1, YY1–E1A and E1A plasmid construction. (B) EMSA of the ORF50p(−199
V–FLAG–YY1, pCMV–FLAG–YY1–E1A, pCMV–FLAG–E1A. The cell extracts were mixed
hift the complexes. (C) Association between proteins and ORF50p(−199 to −168) in
ated at the 5′ end. The probe was incubated with protein extracts prepared from the
(Promega). The bound materials were assayed by immunoblotting with antibodies to
201P.-J. Chang et al. / Virology 413 (2011) 194–204control siRNA transfected cells. This discrepancy may be due to that a
longer period of SB/TPA treatment (N 18 hr) sufﬁciently reduces the
YY1 levels below the minimal extent for transcriptional repression.
Overexpression of YY1 suppresses the KSHV lytic cycle after
SB/TPA treatment
To further determine whether YY1 was involved in the lytic cycle
induction,weestablished a stable cell lineHH-B2(Dox-YY1) that harbors
a doxycycline-regulated YY1 gene. Treatment of the HH-B2(Dox-YY1)
cells with doxycycline was able to produce abundant YY1 (Fig. 5A).
Overeexpression of YY1 in HH-B2(Dox-YY1) did not signiﬁcantly affect
the cell growth andproliferation (Fig. 5B). Using this cell clone,we found
that overexpression of YY1 dramatically affect the expression of viral
lytic genes after SB/TPA treatment (Fig. 5C). Notably, doxyclycline did
not affect the SB/TPA-mediated lytic induction in parental HH-B2 cells
(Fig. 5D). These results suggest that YY1 overexpression contributes to
inhibition of the KSHV lytic cycle after SB/TPA treatment.
Activation of the ORF50 promoter by YY1–E1A fusion protein
YY1 can act as a transcriptional repressor or activator by recruiting
the co-repressors or co-activators in response to environmentalFig. 7. Transcriptional activation of thewild-type and YY1-mutated ORF50p reporters by ORF
at least three experiments, with the standard deviations shown.stimuli (Shi et al., 1997). Since the adenovirus 13S E1A protein
interacts with YY1 protein and functions as a co-activator in many
YY1-regulated genes (Lee et al., 1995a, 1995b), a chimeric YY1–E1A
was constructed to mimic the functional interaction between YY1 and
E1A (Fig. 6A). In EMSA experiment, overexpressed YY1 and YY1–E1A
was shown to bind to the ORF50p(−199 to−168) element (Fig. 6B).
Additionally, we also performed a DNA afﬁnity precipitation assay
(DAPA) to pull down the protein complexes that bound to the ORF50
promoter. Similar to EMSA assay, YY1 and YY1–E1A, but not E1A,
speciﬁcally bound to the ORF50 promoter (Fig. 6C).
In transient reporter assays, the YY1–E1A fusion protein consis-
tently exhibited two-fold more efﬁcient in activating the wild-type
ORF50p(−3801/+10) reporter than the reporter containing YY1
mutation in HKB5/B5 and in HH-B2 cells (Fig. 7). In particular, the
activity of YY1–E1A on the ORF50p(−3801/+10) reporter was
comparable to that of ORF50 protein in HKB5/B5 cells and even
stronger than that of ORF50 protein in HH-B2 cells. Mutation at YY1
site in the ORF50 promoter (−3801/+10) did not affect the ORF50
auto-stimulation. Although E1A protein alone might interact with
endogenous YY1 protein, we did not detect its differential activation
on the wild-type and YY1-mutated ORF50p(−3810/+10) reporters.
Two shorter ORF50p reporters, ORF50p(−1365/+10) and ORF50p
(−220/+10) conferred a limited responsiveness to ORF50 protein in50, YY1, E1A and YY1–E1A in HKB5/B5 and HH-B2 cells. The values represent averages of
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still retained a two-fold better activation on the wild-type ORF50p
reporter than on the YY1-mutated reporter, indicating that the YY1
site is critical for mediating the YY1–E1A transactivation (Fig. 7).
YY1–E1A disrupts KSHV latency
To determine whether YY1–E1A induced the KSHV lytic cycle in
latently infected cells, activation of the ORF50 gene was examined in
HH-B2 cells. As shown in Fig. 8A, YY1–E1A signiﬁcantly activated the
ORF50 mRNA expression detected by reverse transcription-PCR,
although the transactivation function of YY1–E1A was lower thanFig. 8. Disruption of KSHV latency by YY1–E1A fusion protein. (A) Activation of the endogeno
treated with sodium butyrate were harvested at 20 hr after treatment. The ORF50mRNAwas
cells. RNA samples were obtained at 40 hr after transfection. Hybridization was carried out
reporters in HKB5/B5 and HH-B2 cells. Four viral lytic reporters containing the ORF50 responthat of ORF50. We also performed a Northern blot analysis to examine
the activation of the PAN RNA by ORF50, E1A, YY1 and YY1–E1A.
Similarly, the fused YY1–E1A protein signiﬁcantly activated the PAN
RNA in HH-B2 cells (Fig. 8B). To further conﬁrm the disruption of
KSHV latency by YY1–E1A, four lytic cycle reporters that contain the
ORF50 response elements from the PAN, K12, K6 (vMIP-1) and ORF57
promoters were used in transient transfection assays. In HKB5/B5
cells, YY1–E1A could not activate these four reporters (Fig. 8C).
However, YY1–E1A activated these viral reporters in HH-B2 cells
(Fig. 8C), suggesting that activation of the viral reporters by YY1–E1A
in the KSHV-positive cells is mediated through the induction of the
ORF50 gene expression.us ORF50 mRNA in HH-B2 cells. HH-B2 cells transfected with the indicated plasmids or
detected by an RT-PCR assay. (B) Northern analysis of the PAN RNA expression in HH-B2
as described in Materials and methods. (C) Transcriptional activation of the viral lytic
se elements from the PAN, K12, K6 and ORF57 promoters were used in luciferase assays.
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The KSHV ORF50 protein is a multifunctional replication and
transcription activator that plays a key role to initiate the viral
reactivation from latency (Sun et al., 1998; Wang et al., 2004b). To
ensure a proper propagation of the virus under different conditions,
KSHV in cells is known to evolve various independent pathways to
regulate the ORF50 gene expression. In this report, we reveal that
YY1 protein directly binds to the promoter of the ORF50 gene in
vitro and in vivo (Fig. 2). The YY1 binding site is located between
−184 and −176 of the ORF50 promoter, which does not overlap
with the previously known regulatory elements (Fig. 1). During
lytic induction by treating cells with SB and TPA, we found that the
levels of YY1 protein in cells are signiﬁcantly decreased, which is
most likely mediated through post-translational mechanism
(Fig. 3). By three different criteria, the data presented in this
study strongly suggest that YY1 serves as a repressor to prevent the
SB/TPA-mediated activation of the ORF50 promoter: i) mutation of
the YY1 binding site in the ORF50 promoter confers a better
response to SB and TPA (Fig. 4A); ii) reinforcing YY1 down-
regulation by siRNAs in the SB/TPA-treated cells signiﬁcantly
increases the ORF50p activation at initial phase (Fig. 4C); iii)
overexpression of YY1 blocks the activation of the ORF50p reporter
in transient transfection, as well as represses the expression of the
ORF50 gene and its downstream lytic genes in the SB/TPA-treated
cells (Figs. 4B and 5). Although YY1 acts as a repressor in blocking
the lytic induction after SB and TPA treatment, different stimuli
may have different effects on the function of YY1 in KSHV
reactivation from latency. Besides functioning as a repressor as
described above, we show that YY1 can also function as a
transcriptional activator in regulating the ORF50 promoter under
certain conditions. As shown in Figs. 7 and 8, a chimeric YY1–E1A
fusion, which links YY1 and its coactivator E1A, is able to activate
the ORF50 promoter (Figs. 7 and 8). Due to the dual roles of YY1 in
the KSHV reactivation, we propose that positive or negative
regulation of the YY1 activity is an important control in the switch
between KSHV latency and lytic cycle (Fig. 9).
Repressive role of YY1 in the latent-lytic switch of gammaherpesviruses
YY1 is one of the Polycomb group (PcG) proteins that are
responsible for the heritable silencing of developmentally important
genes (Atchison et al., 2003; Wilkinson et al., 2006). It may
potentially function as a repressor in many viruses to maintain
viral persistence or prevent viral reactivation. In addition to KSHV,
YY1 protein is also known to suppress the latent-lytic switch of
Epstein–Barr virus (EBV), a gamma herpesvirus that is closely
related to KSHV. In EBV, YY1 protein negatively regulates theFig. 9. Proposed model for the role of YY1 in the latent-lytic switch. The YY1 protein
binding to the ORF50 promoter serves as a repressor to prevent the KSHV lytic
replication induced by SB and TPA. Under different inducing conditions, YY1 may act as
an activator for the ORF50 promoter activation by recruiting the co-activators.transcription of two immediate-early genes, BRLF1 and BZLF1, thus
maintaining the virus under latency (Montalvo et al., 1995; Zalani
et al., 1997). Particularly, the gene product of BRLF1 is a homolog of
KSHV ORF50 protein (Russo et al., 1996). There are two important
conclusions from these studies. First, YY1 was shown to repress the
basal promoter activity of both BZLF1 and BRLF1 genes in latently
EBV-infected cells (Montalvo et al., 1995; Zalani et al., 1997).
Mutation at the YY1 sites in either the BZLF1 or BRLF1 promoter
enhanced the basal promoter activity. Secondly, different inducers
that activate EBV lytic cycle may have different effects on the YY1
function during lytic induction. Montalvo et al. have compared the
level and function of YY1 between latent and lytic conditions in two
EBV-infected cell lines, Raji and Akata (Montalvo et al., 1995). They
found that the levels of YY1 protein remained unchanged, but the
DNA-binding activity of YY1 was completely lost in Raji cells after
TPA treatment. However, no changes on the YY1 level and its DNA-
binding activity were detected in an EBV-infected cell line, Akata,
treated with anti-IgG.
Unlike the action of YY1 in EBV, YY1 protein binding to the
ORF50 promoter under latent condition did not signiﬁcantly
suppress the basal promoter activity. Mutation at the YY1 binding
site in the ORF50 promoter did not increase the promoter activity
in either KSHV-negative or KSHV-positive cells (Fig. 4A). However,
the ORF50 promoter became more sensitive to SB and TPA
treatment after removal of YY1 binding. During the lytic induction
after SB and TPA treatment, down-regulation of the YY1 levels was
observed in our study. Here we speculate that YY1 may function to
be a latent-lytic checkpoint in cells to prevent the lytic induction
of KSHV.
Positive role of YY1 in the latent-lytic switch of KSHV
In our study, we have created an YY1–E1A fusion protein that
links YY1 to its coactivator E1A. When the plasmid expressing this
“active” YY1–E1A was transfected into cells, the fusion protein
activated the ORF50 promoter and induced the lytic replication in
latently KSHV-infected cells (Figs. 7 and 8). These ﬁndings suggest
that YY1 can serve as an activator to disrupt viral latency under
certain conditions. However, the stimuli that activate the function
of YY1 still remain elusive. One potentially biological stimulus that
can induce the global YY1 activation is the infection with
adenoviruses. As noted in Fig. 8, we did not observed the positive
effect of the ectopic E1A on the lytic induction in latently KSHV-
infected cells. Possibly, low efﬁcient interaction between YY1 and
E1A occurs on the ORF50 promoter under our conditions. The
future work may need to characterize whether different combina-
tions of the physiological and environmental stimuli could activate
the YY1 transactivation.
In summary, this report provides evidence for the regulation of the
ORF50 promoter by YY1. Under SB and TPA treatment, YY1 functions
as a repressor to prevent the ORF50p activation. On the other hand,
functional activation of YY1 is sufﬁcient to activate the ORF50
promoter. Although we do not know the authentic stimuli that
control YY1 activity in the KSHV-infected cells, activation or
repression of YY1 activity may play an important role in regulating
the switch between KSHV latency and lytic cycle.
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